tyrosyl-seryl(o-t-butyl)-glycyl-phenylalanyl-leucyl-threonine(o-t-butyl) has been researched along with devazepide in 1 studies
| Studies (tyrosyl-seryl(o-t-butyl)-glycyl-phenylalanyl-leucyl-threonine(o-t-butyl)) | Trials (tyrosyl-seryl(o-t-butyl)-glycyl-phenylalanyl-leucyl-threonine(o-t-butyl)) | Recent Studies (post-2010) (tyrosyl-seryl(o-t-butyl)-glycyl-phenylalanyl-leucyl-threonine(o-t-butyl)) | Studies (devazepide) | Trials (devazepide) | Recent Studies (post-2010) (devazepide) |
|---|---|---|---|---|---|
| 15 | 0 | 0 | 780 | 5 | 42 |
| Protein | Taxonomy | tyrosyl-seryl(o-t-butyl)-glycyl-phenylalanyl-leucyl-threonine(o-t-butyl) (IC50) | devazepide (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | 0.0009 | |
| Gastrin/cholecystokinin type B receptor | Rattus norvegicus (Norway rat) | 0.0008 | |
| Cholecystokinin receptor type A | Homo sapiens (human) | 0.0002 | |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | 0.245 | |
| Cholecystokinin receptor type A | Cavia porcellus (domestic guinea pig) | 0.27 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noble, F; Roques, BP; Smadja, C | 1 |
1 other study(ies) available for tyrosyl-seryl(o-t-butyl)-glycyl-phenylalanyl-leucyl-threonine(o-t-butyl) and devazepide
| Article | Year |
|---|---|
Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists.
Topics: Amino Acid Sequence; Analgesia; Animals; Benzodiazepinones; Cholecystokinin; Devazepide; Disulfides; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Male; Mice; Molecular Sequence Data; Naloxone; Naltrexone; Oligopeptides; Peptide Fragments; Phenylalanine; Receptors, Opioid, delta; Receptors, Opioid, mu; Sincalide | 1994 |